Starší publikace (2019–2021)

Publikace 2021

MM a MGUS

  1. Auner HW, Gavriatopoulou M, Delimpasi S, Simonova M, Spicka I, Pour L, Dimopoulos MA, Kriachok I, Pylypenko H, Leleu X, Doronin V, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD Jr, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol. 2021 Jun 1;96(6):708-718. doi: 10.1002/ajh.26172. Epub 2021 May 3.PMID: 33755235.  IF 10,047
  2. Bezdekova R, Jelinek T, Kralova R, Stork M, Polackova P, Vsianska P, Brozova L, Jarkovsky J, Almasi M, Boichuk I, Knechtova Z, Penka M, Pour L, Sevcikova S, Hajek R, Rihova L. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. Br J Haematol. 2021 Oct;195(1):95-107. doi: 10.1111/bjh.17713. Epub 2021 Sep 9.PMID: 34500493. IF 6,998
  3. Bisht K, Walker B, Kumar SK, Spicka I, Moreau P, Martin T, Costa LJ, Richter J, Fukao T, Macé S, van de Velde H. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol. 2021 Dec;14(12):1099-1114.  doi: 10.1080/17474086.2021.1983427. Epub 2021 Oct 8. PMID: 34551651. IF 2,929
  4. Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.PMID: 33839618. IF 3,156
  5. D'Agostino M, Larocca A, Offidani M, Liberati AM, Gaidano G, Petrucci MT, Derudas D, Capra A, Zambello R, Cascavilla N, de Fabritiis P, Innao V, Bonello F, Patriarca F, Benevolo G, Giuliani N, Aitoro G, Guglielmelli T, Di Raimondo F, Corradini P, Musto P, Hájek R, Sonneveld P, Boccadoro M, Bringhen S. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.PMID: 33846296 IF 11,037
  6. Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10.PMID: 33970288. IF 3,673
  7. Demel I, Bago JR, Hajek R, Jelinek T. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2021 May;193(4):705-722. doi: 10.1111/bjh.17235. Epub 2020 Nov 20.PMID: 33216972. IF 6,998
  8. Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.PMID: 34087126. IF 41,316
  9. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere. 2021 Feb 3;5(2):e528. doi: 10.1097/HS9.0000000000000528. eCollection 2021 Feb.PMID: 33554050 
  10. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U; EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.PMID: 33549387. IF 32,976
  11. Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, van Rhee F, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Bařinová M, Kuhn M, Šilar J, Čápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021 Jul;17(19):2499-2512. doi: 10.2217/fon-2020-1225. Epub 2021 Mar 26.PMID: 33769076. IF 3,404
  12. Hulin C, Beksac M, Goodman HJ, Spicka I, Alegre A, Prince M, Campana F, Finn G, Le-Guennec S, Macé S, Muccio S, Tavernier A, Rouchon MC, Richardson PG. Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. Blood Cancer J. 2021 Oct 20;11(10):169. doi: 10.1038/s41408-021-00562-9.PMID: 34671024. IF 11,037
  13. Hungria V, Beksac M, Weisel KC, Nooka AK, Masszi T, Spicka I, Munder M, Mateos MV, Mark TM, Qi M, Qin X, Fastenau J, Spencer A, Sonneveld P, Garvin W, Renaud T, Gries KS. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. Br J Haematol. 2021 May;193(3):561-569. doi: 10.1111/bjh.17321. Epub 2021 Feb 8.PMID: 33555030. IF 6,998
  14. Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021 Mar;192(5):869-878. doi: 10.1111/bjh.16980. Epub 2020 Jul 30.PMID: 33216361. IF 6,998
  15. Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Ann Hematol. 2021 Jan;100(1):297-302. doi: 10.1007/s00277-020-04302-0.PMID: 33106909. IF 3,673
  16. Knight A, Rihova L, Kralova R, Penka M, Adam Z, Pour L, Piskacek M, Hajek R. Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma. J Clin Med. 2021 Aug 20;10(16):3717. doi: 10.3390/jcm10163717.PMID: 34442012. IF 4,242
  17. Knop S, Mateos MV, Dimopoulos MA, Suzuki K, Jakubowiak A, Doyen C, Lucio P, Nagy Z, Usenko G, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Losava G, Fujisaki T, Garg M, Wang J, Wroblewski S, Kudva A, Gries KS, Fastenau J, San-Miguel J, Cavo M. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021 Jun 2;21(1):659. doi: 10.1186/s12885-021-08325-2.PMID: 34078314. IF 4,43
  18. Krejci M, Pour L, Adam Z, Sandecka V, Stork M, Sevcikova S, Krejci M, Knechtova Z, Kral Z. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Ann Hematol. 2021 Oct;100(10):2541-2546. doi: 10.1007/s00277-021-04594-w. Epub 2021 Jul 26.PMID: 34309714. IF 3,673
  19. Kriegova E, Fillerova R, Minarik J, Savara J, Manakova J, Petrackova A, Dihel M, Balcarkova J, Krhovska P, Pika T, Gajdos P, Behalek M, Vasinek M, Papajik T. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. 2021 Jul 19;11(1):14671. doi: 10.1038/s41598-021-93835-z.PMID: 34282158. IF 4,38
  20. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021 Jan;22(1):142-154. doi: 10.1016/S1470-2045(20)30680-X. Epub 2020 Dec 7.PMID: 33301738. IF 41,316
  21. Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Zhang J, Obreja M, Qi M, Oriol A, Siegel D. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma. 2021 Feb;62(2):358-367. doi: 10.1080/10428194.2020.1832672. Epub 2020 Oct 28.PMID: 33112184. IF 3,28
  22. Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hajek R, Dimopoulos MA, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos MV, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021 Jan;35(1):31-44.  doi: 10.1038/s41375-020-01016-0. Epub 2020 Aug 19. IF 11,528
  23. Mateos MV, Gavriatopoulou M, Facon T, Auner HW, Leleu X, Hájek R, Dimopoulos MA, Delimpasi S, Simonova M, Špička I, Pour L, Kriachok I, Pylypenko H, Doronin V, Usenko G, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros AZ, Anderson LD Jr, Bahlis NJ, Cavo M, Chai Y, Jeha J, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. J Hematol Oncol. 2021 Apr 13;14(1):59. doi: 10.1186/s13045-021-01071-9.PMID: 33849608. IF 17,388
  24. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Iida S, Bladé J, Ukropec J, Pei H, Van Rampelbergh R, Kudva A, Qi M, San-Miguel J. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):785-798. doi: 10.1016/j.clml.2021.06.005. Epub 2021 Jun 18.PMID: 34344638. IF 3,231
  25. Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021 May 12;11(5):89. doi: 10.1038/s41408-021-00478-4.PMID: 33980831 IF 11,037
  26. Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, Pour L, Pavlicek P, Mistrik M, Brozova L, Krhovska P, Machalkova K, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Capkova L, Sykora M, Kessler P, Stejskal L, Heindorfer A, Ullrychova J, Skacel T, Maisnar V, Hajek R. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.PMID: 33451293. IF 4,43
  27. Minarik J, Szotkowski T, Hrbek J, Krhovska P, Buriankova E, Proskova J, Pika T, Bacovsky J. A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma. Clin Case Rep. 2021 Aug 6;9(8):e04570. doi: 10.1002/ccr3.4570. eCollection 2021 Aug.PMID: 34401156 IF
  28. Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4.PMID: 34097854. IF 79,323
  29. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.PMID: 33662288. IF 41,316
  30. Motais B, Charvátová S, Walek Z, Hrdinka M, Smolarczyk R, Cichoń T, Czapla J, Giebel S, Šimíček M, Jelínek T, Ševčíková T, Sobotka J, Kořístek Z, Hájek R, Bagó JR. Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. Cells. 2021 Apr 21;10(5):967. doi: 10.3390/cells10050967.PMID: 33919155. IF 6,6
  31. Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 Feb 1;11(2):24. doi: 10.1038/s41408-021-00408-4.PMID: 33563895. IF 11,037
  32. Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, Van de Donk N, Terpos E, Broijl A, De Larrea CF, Gay F, Goldschmidt H, Hajek R, Vangsted AJ, Zamagni E, Zweegman S, Cavo M, Dimopoulos M, Einsele H, Ludwig H, Barosi G, Boccadoro M, Mateos MV, Sonneveld P, Miguel JS. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.PMID: 34261295. IF 9,941
  33. Oliva S, Bruinink DHO, Rihova L, D'Agostino M, Pantani L, Capra A, van der Holt B, Troia R, Petrucci MT, Villanova T, Vsianska P, Jugooa R, Brandt-Hagens C, Gilestro M, Offidani M, Ribolla R, Galli M, Hajek R, Gay F, Cavo M, Omedé P, van der Velden VHJ, Boccadoro M, Sonneveld P. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0.PMID: 34083504. IF 11,037
  34. Radocha J, Jelinek T, Pour L, Spicka I, Minarik J, Popkova T, Jungova A, Pavlicek P, Brozova L, Stork M, Sedlak F, Krhovska P, Maisnar V, Heindorfer A, Sykora M, Wrobel M, Mikula P, Kessler P, Ullrychova J, Hajek R. Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation. Int J Lab Hematol. 2021 Oct;43(5):e244-e247. doi: 10.1111/ijlh.13460. Epub 2021 Jan 16.PMID: 33452712. IF 2,877
  35. Radocha J, van de Donk NWCJ, Weisel K. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers (Basel). 2021 Mar 29;13(7):1571. doi: 10.3390/cancers13071571.PMID: 33805481 IF 6,639
  36. Richard S, Chari A, Delimpasi S, Simonova M, Spicka I, Pour L, Kriachok I, Dimopoulos MA, Pylypenko H, Auner HW, Leleu X, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD Jr, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chang H, Landesman Y, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Grosicki S, Richardson PG. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol. 2021 Sep 1;96(9):1120-1130. doi: 10.1002/ajh.26261. Epub 2021 Jul 5.PMID: 34062004. IF 10,047
  37. Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 1;39(22):2430-2442. doi: 10.1200/JCO.21.00972. Epub 2021 Jun 11.PMID: 34111952. IF 44,544
  38. Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 Aug;194(3):496-507. doi: 10.1111/bjh.17338. Epub 2021 Mar 16.PMID: 33724461. IF 6,998
  39. Sandecká V, Pour L, Špička I, Minařík J, Radocha J, Jelínek T, Heindorfer A, Pavlíček P, Sýkora M, Jungová A, Kessler P, Wróbel M, Starostka D, Ullrychová J, Stejskal L, Štork M, Straub J, Pika T, Brožová L, Ševčíková S, Maisnar V, Hájek R. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. Eur J Haematol. 2021 Oct;107(4):466-474. doi: 10.1111/ejh.13683. Epub 2021 Jul 28.PMID: 34272773. IF 2,997
  40. Steiner N, Abdel Hamid A, Kronbichler A, Neuwirt H, Myslivecek M, Kollar M, Lachmanova J, Rysava R, Hruskova Z, Spicka I, Willenbacher W, Nachbaur D, Wolf D, Tesar V, Gunsilius E. Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury. J Nephrol. 2021 Aug;34(4):1263-1270. doi: 10.1007/s40620-020-00939-2. Epub 2020 Dec 31.PMID: 33382447. IF 3,902
  41. Stork M, Bezdekova R, Kralova R, Sandecka V, Adam Z, Krejci M, Boichuk I, Knechtova Z, Brozova L, Sevcikova S, Rihova L, Pour L. Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant. Neoplasma. 2021 May;68(3):519-527. doi: 10.4149/neo_2021_200814N861. Epub 2021 Feb 24.PMID: 33618517. IF 2,575
  42. Sanchez L, Leleu X, Beaumont JL, Yu H, Hudgens S, Simonova M, Auner HW, Quach H, Delimpasi S, Špička I, Pour L, Kriachok I, Dimopoulos MA, Usenko G, Hájek R, Benjamin R, Sinha DK, Venner C, Illmer T, Garg MK, Stevens DA, Jagannath S, Levy M, Anderson LD Jr, Bahlis NJ, Facon T, Cavo M, Chai Y, Ma X, Tang S, Leong H, Shah J, Shacham S, Kauffman M, Richardson P, Grosicki S. Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. Am J Hematol. 2021 Oct 1;96(10):E383-E386. doi: 10.1002/ajh.26282. Epub 2021 Jul 12.PMID: 34161627. IF 10,047
  43. Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Broijl A, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWCJ, Offidani M, Palumbo GA, Spencer A, Boccadoro M, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021 Nov10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. PMID: 34520219. IF 44,544
  44. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 Feb 18;11(2):40. doi: 10.1038/s41408-021-00432-4.PMID: 33602913. IF 11,037
  45. Zaccaria GM, Bertamini L, Petrucci MT, Offidani M, Corradini P, Capra A, Romano A, Liberati AM, Mannina D, de Fabritiis P, Cascavilla N, Ruggeri M, Mina R, Patriarca F, Benevolo G, Belotti A, Gaidano G, Nagler A, Hájek R, Spencer A, Sonneveld P, Musto P, Boccadoro M, Gay F. Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clin Cancer Res. 2021 Jul 1;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29.PMID: 33926915. IF 12,531

Jiné výzkumné projekty 2021

  1. Adam Z, Tomíška M, Řehák Z, Koukalová R, Krejčí M, Král Z, Adamová Z, Ševčíková S, Pour L, Štork M, Krejčí M, Sandecká V. Transformation of IgM-MGUS into Waldenström´s macroglobulinemia in two of six patients treated for Schnitzler´s syndrome. Vnitr Lek. 2021 Summer;67(E-3):15-23.PMID: 34171947 
  2. Gregorova J, Vychytilova-Faltejskova P, Sevcikova S. Epigenetic Regulation of MicroRNA Clusters and Families during Tumor Development. Cancers (Basel). 2021 Mar 16;13(6):1333. doi: 10.3390/cancers13061333.PMID: 33809566. IF 6,639
  3. Chyra Z, Sevcikova T, Vojta P, Puterova J, Brozova L, Growkova K, Filipova J, Zatopkova M, Grosicki S, Barchnicka A, Jedrzejczak WW, Waszczuk-Gajda A, Jungova A, Mikulasova A, Hajduch M, Mokrejs M, Pour L, Stork M, Harvanova L, Mistrik M, Mikala G, Robak P, Czyz A, Debski J, Usnarska-Zubkiewicz L, Jurczyszyn A, Stejskal L, Morgan G, Kryukov F, Budinska E, Simicek M, Jelinek T, Hrdinka M, Hajek R. Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica. 2021 Feb 1;106(2):601-604.  doi: 10.3324/haematol.2019.239756. IF 9,941
  4. Koukalová R, Selingerová I, Řehák Z, Adam Z, Szturz P. FDG-PET/ CT for initial staging and response assessment in Castleman disease - retrospective single-center study of 29 cases. Klin Onkol. 2021 Spring;34(2):120-127. doi: 10.48095/ccko2021120.PMID: 33906360 
  5. Král Z, Řehák Z, Krejčí M, Koukalová R, Ševčíková S, Pour L, Krejčí M, Štork M, Sandecká V, Adam Z. Therapy of 3 patients with Erdhiem-Chester disease with cladribin or cladribin in combination with cyclophosphamide. Case report and review of the therapy. Vnitr Lek. 2021 Summer;67(3):157-164.PMID: 34171955

Publikace 2020

MM a MGUS

  1. Bringhen S, D'Agostino M, Paris L, Ballanti S, Pescosta N, Spada S, Pezzatti S, Grasso M, Rota-Scalabrini D, De Rosa L, Pavone V, Gazzera G, Aquino S, Poggiu M, Santoro A, Gentile M, Baldini L, Petrucci MT, Tosi P, Marasca R, Cellini C, Palumbo A, Falco P, Hájek R, Boccadoro M, Larocca A. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.PMID: 31582542.  IF 9,941
  2. Campioni M, Agirrezabal I, Hajek R, Minarik J, Pour L, Spicka I, Gonzalez-McQuire S, Jandova P, Maisnar V. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. Eur J Health Econ. 2020 Mar;21(2):219-233. doi: 10.1007/s10198-019-01122-6. Epub 2019 Oct 31.PMID: 31673898. IF 3,689
  3. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.PMID: 32359506. IF 18,959
  4. Dimopoulos MA, Niesvizky R, Weisel K, Siegel DS, Hajek R, Mateos MV, Cavo M, Huang M, Zahlten-Kumeli A, Moreau P. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. Blood Cancer J. 2020 Mar 9;10(3):35. doi: 10.1038/s41408-020-0300-y.PMID: 32152297. IF 11,037
  5. Dimopoulos MA, Špička I, Quach H, Oriol A, Hájek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S; TOURMALINE-MM4 study group. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020 Dec 1;38(34):4030-4041. doi: 10.1200/JCO.20.02060. Epub 2020 Oct 6.PMID: 33021870 IF 44,544
  6. Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 Sep 4;10(9):91. doi: 10.1038/s41408-020-00357-4.PMID: 32887873 IF 11,037
  7. Fassmannová D, Sedlák F, Sedláček J, Špička I, Grantz Šašková K. Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma. Cancers (Basel). 2020 Apr 25;12(5):1065. doi: 10.3390/cancers12051065.PMID: 32344880 IF 6,639
  8. Gamberi B, Berthou C, Hernandez M, Semenzato G, Tholouli E, Hájek R, Caers J, Dimopoulos M, Minnema MC, Andreasson B, Parreira J, Crotty G, Remes K, Kueenburg E, Rosettani B, Di Micco A, Peters S, Bacon P, Blau IW. A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e629-e644.  doi: 10.1016/j.clml.2020.05.006. Epub 2020 May 13. IF 3,231
  9. Garcés JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, Alignani D, Calasanz MJ, Growkova K, Goicoechea I, Agirre X, Pour L, Prosper F, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Perez-Montaña A, Garate S, Blanco L, Lasa M, Maiso P, Flores-Montero J, Sanoja-Flores L, Chyra Z, Vdovin A, Sevcikova T, Jelinek T, Botta C, El Omri H, Keats J, Orfao A, Hajek R, San-Miguel JF, Paiva B. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia. 2020 Feb;34(2):589-603. doi: 10.1038/s41375-019-0588-4. Epub 2019 Oct 8. IF 11,528
  10. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N,Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Davila Valls J, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł,González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Długosz-Danecka M, Grosicki S, Vesole DH. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020 May;95(5):503-509. doi: 10.1002/ajh.25758. Epub 2020 Feb 29. PMID: 32072687. IF 10,047
  11. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Valls JD, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Mazur P, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Długosz-Danecka M, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Vesole DH. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2020 Aug;61(8):1885-1893. doi: 10.1080/10428194.2020.1749605. Epub 2020 Apr 19. PMID: 32306794. IF 3,28
  12. Hájek R, Gonzalez-McQuire S, Szabo Z, Delforge M, DeCosta L, Raab MS, Bouwmeester W, Campioni M, Briggs A. Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. BMJ Open. 2020 Jul 14;10(7):e034209. doi: 10.1136/bmjopen-2019-034209.PMID: 32665382. IF 2,692
  13. Hájek R, Sandecka V, Špička I, Raab M, Goldschmidt H, Beck S, Minařík J, Pavlíček P, Radocha J, Heindorfer A, Jelínek T, Stejskal L, Brožová L, Ševčíková S, Straub J, Pika T, Pour L, Maisnar V, Seckinger A, Hose D. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. Br J Haematol. 2020 Jul;190(2):189-197. doi: 10.1111/bjh.16572. Epub 2020 Mar 12.PMID: 32163180. IF 6,998
  14. Hajek R, Pour L, Ozcan M, Martin Sánchez J, García Sanz R, Anagnostopoulos A, Oriol A, Cascavilla N, Terjung A, Lee Y, Briso EM, Dobkowska E, Hauns B, Špička I. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Eur J Haematol. 2020 May;104(5):435-442. doi: 10.1111/ejh.13377. Epub 2020 Mar 7.PMID: 31883396. IF 2,997
  15. Hradska K, Kascak M, Hajek R, Jelinek T. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. Expert Rev Hematol. 2020 Apr;13(4):375-392. doi: 10.1080/17474086.2020.1733405. Epub 2020 Mar 2.PMID: 32116068. IF 2,929
  16. Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol. 2020 Apr;13(4):421-433. doi: 10.1080/17474086.2020.1729734. Epub 2020 Mar 9.PMID: 32148109. IF 2,929
  17. Chattopadhyay S, Thomsen H, Weinhold N, Meziane I, Huhn S, da Silva Filho MI, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Houlston R, Goldschmidt H, Hemminki K, Försti A. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. Leukemia. 2020 Apr;34(4):1187-1191. doi: 10.1038/s41375-019-0619-1. Epub 2019 Nov 6.PMID: 31695157. IF 11,528
  18. Jelinek T, Popkova T, Duras J, Mihalyova J, Kascak M, Benkova K, Plonkova H, Cerna L, Koristek Z, Simicek M, Hajek R. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort. Hematol Oncol. 2020 Aug;38(3):412-414. doi: 10.1002/hon.2736. Epub 2020 Apr 23.PMID: 32323881. IF 5,271
  19. Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Ann Hematol. 2020 Aug;99(8):1793-1804. doi: 10.1007/s00277-020-04149-5. Epub 2020 Jul 1.PMID: 32613281. IF 3,673
  20. Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica. 2020 Apr;105(4):1074-1080. doi: 10.3324/haematol.2019.220657. Epub 2019 Jun 27.PMID: 31248973. IF 9,941
  21. Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leuk Lymphoma. 2020 Feb;61(2):377-386.  doi: 10.1080/10428194.2019.1666381.  Epub 2019 Sep 26. IF 3,28
  22. Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020.PMID: 31221782. IF 9,941
  23. Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ.. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23.PMID: 32213342 Clinical Trial. IF 18,959
  24. Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica. 2020 Jan;105(1):193-200. doi: 10.3324/haematol.2019.219139. Epub 2019 Jun 20. IF 9,941
  25. Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, Krejci M, Auner HW, Pohlreich D, Hayden P, Basak GW, Lenhoff S, Schaap N, van Biezen A, Knol C, Iacobelli S, Liu Q, Celanovic M, Garderet L, Kröger N. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplant. 2020 Feb;55(2):356-366.  doi: 10.1038/s41409-019-0676-0. Epub 2019 Sep 18. IF 5,483
  26. Richardson PG, Beksaç M, Špička I, Mikhael J. Isatuximab for the treatment of relapsed/refractory multiple myeloma. Expert Opin Biol Ther. 2020 Dec;20(12):1395-1404.  doi: 10.1080/14712598.2021.1841747. IF 4,388
  27. Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos M. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. Eur J Haematol. 2020 May;104(5):443-458. doi: 10.1111/ejh.13379. Epub 2020 Feb 22.PMID: 31880006 IF 2,22
  28. Stork M, Sevcikova S, Brozova L, Spicka I, Maisnar V, Minarik J, Jungova A, Gregora E, Velichova R, Hajek R, Jelinek T, Pour L. Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data. Neoplasma. 2020 Jan;67(1):178-184. doi: 10.4149/neo_2019_190430N383. Epub 2019 Dec 9.PMID: 31829027. IF 2,575
  29. Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, van de Donk NWCJ, Avet-Loiseau H, Hajek R, Vangsted AJ, Ludwig H, Zweegman S, Moreau P, Einsele H, Boccadoro M, San Miguel J, Dimopoulos MA, Sonneveld P. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020 Aug;34(8):2000-2011. doi: 10.1038/s41375-020-0876-z. Epub 2020 May 22.PMID: 32444866. IF 11,528
  30. Terpos E, Ramasamy K, Maouche N, Minarik J, Ntanasis-Stathopoulos I, Katodritou E, Jenner MW, Plonkova H, Gavriatopoulou M, Vallance GD, Pika T, Kotsopoulou M, Kothari J, Jelinek T, Kastritis E, Aitchison R, Dimopoulos MA, Zomas A, Hajek R. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma Ann Hematol. 2020 May;99(5):1049-1061. doi: 10.1007/s00277-020-03981-z. Epub 2020 Apr 1.PMID: 32236735. IF 3,673
  31. Vrabel D, Sedlarikova L, Besse L, Rihova L, Bezdekova R, Almasi M, Kubaczkova V, Brožová L, Jarkovsky J, Plonkova H, Jelinek T, Sandecka V, Stork M, Pour L, Sevcikova S, Hajek R. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. Eur J Haematol. 2020 Mar;104(3):190-197. doi: 10.1111/ejh.13358. Epub 2019 Dec 20.PMID: 31763708. IF 2,997
  32. Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka A, Quach H, Munder M, Lee C, Barreto W, Corradini P, Min CK, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Casneuf T, DeAngelis N, Amin H, Ukropec J, Kobos R, Mateos MV. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol. 2020 Aug 20;13(1):115. doi: 10.1186/s13045-020-00948-5.PMID: 32819447 IF 17,388

Jiné výzkumné projekty 2020

  1. Popkova T, Hajek R, Jelinek T. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020 Apr;189(2):228-238. doi: 10.1111/bjh.16436. Epub 2020 Feb 18.PMID: 32072615. IF 6,998
  2. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, Mollee P, Hájek R, Moreau P, Jaccard A, Schönland SO, Filshie R, Nicolas-Virelizier E, Augustson B, Mateos MV, Wechalekar A, Hachulla E, Milani P, Dimopoulos MA, Fermand JP, Foli A, Gavriatopoulou M, Klersy C, Palumbo A, Sonneveld P, Johnsen HE, Merlini G, Palladini G. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. J Clin Oncol. 2020 Oct 1;38(28):3252-3260.  doi: 10.1200/JCO.20.01285. Epub 2020 Jul 30. IF 44,544

 

Publikace 2019

MM a MGUS

  1. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.PMID: 31735560. IF 60,392
  2. Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, Seny GM, Glickman S, Jayabalan DS, Niesvizky R, Gozzetti A, Wiśniewska-Piąty K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Hus I, Guzicka R, Radocha J, Milunovic V, Davila J, Gentile M, Castillo JJ, Jurczyszyn A. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019 Oct;94(10):1132-1140. doi: 10.1002/ajh.25579. Epub 2019 Aug 13. IF 6,973
  3. Bonello F, Pulini S, Ballanti S, Gentile M, Spada S, Annibali O, Omedé P, Ronconi S, Cangialosi C, Podda L, Palmas A, Malfitano A, Rivoli G, Belotti A, Ciambelli F, Vincelli ID, Cafro AM, Innao V, Palumbo A, Sonneveld P, Spencer A, Hájek R, Boccadoro M, Gay F. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. Cancers (Basel). 2019 Nov 5;11(11):1735. doi: 10.3390/cancers11111735.PMID: 31694338. IF 6,126
  4. Bouwmeester W, Briggs A, van Hout B, Hájek R, Gonzalez-McQuire S, Campioni M, DeCosta L, Brozova L. Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. Oncol Ther. 2019 Dec;7(2):141-157. doi: 10.1007/s40487-019-00100-5. Epub 2019 Nov 3.PMID: 32699987.
  5. Butova R, Vychytilova-Faltejskova P, Souckova A, Sevcikova S, Hajek R. Long Non-Coding RNAs in Multiple Myeloma. Noncoding RNA. 2019 Jan 24;5(1). pii: E13. doi: 10.3390/ncrna5010013. Review.
  6. Deulofeu M, Kolářová L, Salvadó V, María Peña-Méndez E, Almáši M, Štork M, Pour L, Boadas-Vaello P, Ševčíková S, Havel J, Vaňhara P. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma. Sci Rep. 2019 May 28;9(1):7975. doi: 10.1038/s41598-019-44215-1. IF 3,998
  7. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. IF 60,392
  8. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28. IF 17,543
  9. Gonzalez-McQuire S, Dimopoulos MA, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. MDM Policy Pract. 2019 Jan 17;4(1):2381468318814253. doi: 10.1177/2381468318814253. eCollection 2019 Jan-Jun.
  10. Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. Br J Haematol. 2019 Nov;187(4):447-458. doi: 10.1111/bjh.16105. Epub 2019 Aug 6. IF 5,518
  11. Jelinek T, Adamusova L, Popkova T, Tvrda I, Smejkalova J, Simicek M, Salounova D, Kascak M, Mihalyova J, Plonkova H, Duras J, Navratil M, Hajek R, Koristek Z. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma. Bone Marrow Transplant. 2019 Jul;54(7):1107-1114. doi: 10.1038/s41409-018-0396-x. Epub 2018 Nov 20. IF 4,725
  12. Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25. IF 6,973
  13. Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leuk Lymphoma. 2019 Feb;60(2):471-476. doi: 10.1080/10428194.2018.1480766. Epub 2018 Jul 22. IF 2,969
  14. JKrál Z, Adam Z, Folber F, Moulis M, Tomíška M, Říhová L, Štork M, Buliková A, Pour L, Krejčí M, Sandecká V, Koukalová R, Řehák Z, Čermáková Z. Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma. Vnitr Lek. Winter 2019;65(1):37-44.
  15. Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.PMID: 31558804  IF 5,791
  16. Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Feb 22;9(3):23. doi: 10.1038/s41408-019-0181-0. IF 8,023
  17. Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova E, Radocha J, Gregora E, Stecova N, Jelinek T, Jungova A, Kralikova E, Brozova L, Hajek R. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Neoplasma. 2019 May 23;66(3):499-505. doi: 10.4149/neo_2018_180824N644. Epub 2019 Feb 14. IF 1,721
  18. Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283. doi: 10.5507/bp.2018.064. Epub 2018 Nov 6. IF 1,0
  19. Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, San Miguel JF, Einsele H. CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22. IF 7,116
  20. Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28. IF 10,107
  21. Radocha J, Hájek R, Brožová L, Pour L, Špička I, Minařík J, Gregora E, Jungová A, Jelínek T, Heindorfer A, Sýkora M, Maisnar V. Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis. Ann Hematol. 2019 Apr;98(4):951-962. doi: 10.1007/s00277-018-3568-2. Epub 2018 Dec 11. IF 2,904
  22. Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019 Jul;36:32-39. doi: 10.1016/j.blre.2019.04.002. Epub 2019 Apr 13. Review. IF 5,823
  23. Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25. IF 2,904
  24. Steiner N, Hajek R, Nachbaur D, Borjan B, Sevcikova S, Göbel G, Gunsilius E. Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target? Dis Markers. 2019 Jan 27;2019:1806034. doi: 10.1155/2019/1806034. eCollection 2019. IF 2,738
  25. Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. Leukemia. 2019 Jul;33(7):1817-1821. doi: 10.1038/s41375-019-0396-x. Epub 2019 Feb 8. IF 8,665
  26. Vrábel D, Pour L, Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019 Mar;34:56-66. doi: 10.1016/j.blre.2018.11.003.  Epub 2018 Nov 23. Review. IF 5,823
  27. Zavrelova A, Paterova P, Gabalec F, Zak P, Radocha J. Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Jun;163(2):161-165. doi: 10.5507/bp.2018.047. Epub 2018 Sep 7. IF 1,0

Jiné výzkumné projekty 2019

  1. Holub D, Flodrova P, Pika T, Flodr P, Hajduch M, Dzubak P. Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites. Biomed Res Int. 2019 Jan 31;2019:3689091. doi: 10.1155/2019/3689091. eCollection 2019. IF 2,276